Recipharm has announced that Consort Medical will apply for delisting
At 6.00 p.m. on 6 February 2020, Recipharm announced that it controlled approximately 75.9 per cent. of the existing issued share capital of Consort Medical plc (“Consort”).
As Recipharm now controls over 75 per cent. of the share capital, Consort will apply for delisting from the London Stock Exchange and cancellation is expected to take effect from 6 March 2020. Following the delisting, Consort will be re-registered as a private company.
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 7,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 7.2 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com